Stimgenics developed a spinal cord stimulation waveform called differential multiplexed spinal cord stimulation. Marshall Stanton, MD, president of Medtronic’s pain therapies business, said the technology will help create a new treatment option for chronic pain patients.
The technology will be delivered through Medtronic’s Intellis platform, which is an implantable neurostimulator device.
“I’m thrilled that Medtronic has acquired a therapy that has the potential to significantly improve outcomes for chronic pain patients,” said Ricardo Vallejo, MD, PhD, Sterigenics founder.
The financial terms of the acquisition weren’t released, but Medtronic said in a news release that the deal is expected to have a neutral effect on its finances in 2020.
Read the full news release here.
More articles on supply chain:
Healthcare procurement pros unite, set up SHOPP
Medtronic files safety warning in UK over robotic system
Red Cross, NFL tackle blood shortages
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.